Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.15 | -0.07 | -0.14 |
| FCF Yield | 7.41% | -21.64% | -29.32% | -7.27% |
| EV / EBITDA | -4.54 | -1.52 | -3.24 | -8.54 |
| Quality | ||||
| ROIC | -29.45% | -55.19% | -35.13% | -20.84% |
| Gross Margin | 89.26% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.58 | 0.32 | 0.85 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 160.48% | 40.36% | -52.51% | -161.31% |
| Safety | ||||
| Net Debt / EBITDA | 2.49 | 0.60 | 0.07 | 4.89 |
| Interest Coverage | 0.00 | 0.00 | -29.86 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -772.90 | -654.21 | 0.00 | 0.00 |